National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No. 7) (No. PB 54 of 2011) (Cth)
PB 54 of 2011
National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No. 7)
National Health Act 1953
___________________________________________________________________________
I, FELICITY MCNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 22 July 2011
FELICITY MCNEILL
Acting First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
1 Name of Instrument
(1)This Instrument is the National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No.7).
(2)This Instrument may also be cited as PB 54 of 2011.
2 Commencement
This Instrument commences on 1 August 2011.
3 Amendments to PB 117 of 2010
Schedule 1 amends the National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2010 (PB 117 of 2010).
.
Schedule 1 Amendments
Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL for the brand DBL Docetaxel Concentrated Injection with Maximum Quantity 1
omit from the column headed “Circumstances”:
C3292
Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL for the brand DBL Docetaxel Concentrated Injection with Maximum Quantity 2
(a) omit from the column headed “Circumstances”:
C3292
(b) omit from the column headed “Purposes”:
P3292
Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL for the brand DBL Docetaxel Concentrated Injection
omit from the column headed “Circumstances”:
C3292
Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 160 mg in 16 mL
omit from the column headed “Circumstances”:
C3292
Schedule 1, omit entry for Dolasetron
Schedule 1, entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL
omit:
| Irinotecan Sandoz | SZ | EMP | C3184 | 2 | 3 |
Schedule 3, omit entry for Dolasetron
Schedule 4,
substitute:
| Listed Drug | Form | Manner of Administration | Brand | Quantity or Number of Units | Approved Ex-manufacturer Price | Claimed Ex-manufacturer Price |
| Bleomycin | Powder for injection containing bleomycin sulfate 15,000 I.U. (with any determined brand of sodium chloride injection as the required solvent) | Injection | Hospira Pty Ltd | 1 | $40.89 | $77.67 |
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See
0
0
0